Zydus Wellness Ltd. News and Updates

Name: Latest research reports of Zydus Wellness Ltd. authored by Sharekhan and published by - Trendlyne research reports.
Item: Zydus Wellness Ltd.
Rating: 5
Author: Sharekhan

Keep track of all breaking news on Zydus Wellness Ltd. from all sources in a single place.

Load latest

Zydus Wellness Ltd.

12 Mar 2025

2023.70

0.61%

Zydus gains FDA approval for urinary tract infection medication

Business Line

The approval strengthens Zydus' position in the US pharmaceutical market, bringing the company's total to 419 USFDA approvals

Zydus Wellness Ltd. has an average target of 2054.00 from 3 brokers.

Zydus Life Gets USFDA Nod To Make Generic UTI Treatment Drug

NDTV Profit | 12 Mar 2025 4 more

Zydus Wellness Ltd.

11 Mar 2025

2023.70

0.61%

Zydus Lifesciences to buy 85% stake in Amplitude Surgical for 256 mn euros

Business Standard

Zydus Lifesciences on Tuesday said it has entered into exclusive negotiations to acquire a majority stake in France-based Amplitude Surgical for 256.8 million euros. The company has entered into negotiations with PAI Partners, Amplitude Surgical's management, as well as two minority shareholders to acquire 85.6 per cent of the company's share capital, the Ahmedabad-based drug maker said in a regulatory filing. Purchase consideration amounts to 256.8 million euros for 85.6 per cent of the outstanding shares and voting rights of Amplitude Surgical, it added. Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. The company provides numerous value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. This includes the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of

Zydus Wellness Ltd. has an average target of 2054.00 from 3 brokers.

Zydus Wellness Ltd.

10 Mar 2025

2023.70

0.61%

GoI to announce new incentive policy for pharma research; to kick-start innovation journey:Zydus Lifesciences chairman

Business Line

The fire-side chat was moderated by Kulin Lalbhai, vice-chairman, Arvind Ltd

Zydus Wellness Ltd. has an average target of 2054.00 from 3 brokers.

Zydus Wellness Ltd.

10 Mar 2025

2023.70

0.61%

Zydus Lifesciences Gets USFDA Nod To Market Generic Antifungal Shampoo

NDTV Profit

Ketoconazole shampoo is an antifungal medication used to treat dandruff, fungal infections, and other skin conditions.

Zydus Wellness Ltd. is trading above all available SMAs

Stock to sell today: Zydus Lifesciences (901.15)

Business Line | 10 Mar 2025 1 more

Zydus Wellness Ltd.

06 Mar 2025

2023.70

0.61%

Zydus Lifesciences shares fly 7% as USFDA okays cancer drug Dasatinib

Business Standard

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to manufacture Dasatinib tabs, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg

Zydus Wellness Ltd. is trading above all available SMAs

Zydus Lifesciences' Dasatinib Tablets Get USFDA Approval, To Manufacture At Ahmedabad Unit

NDTV Profit | 05 Mar 2025 2 more

Zydus Wellness Ltd.

04 Mar 2025

2023.70

0.61%

Zydus Life to develop world's first dual vaccine for typhoid and Shigella

Business Standard

Typhoid and shigellosis remain serious public health threats, particularly in low-resource settings

Zydus Wellness Ltd. is trading above all available SMAs

Zydus To Develop Combination Vaccine For Shigellosis And Typhoid

NDTV Profit | 04 Mar 2025

Zydus Wellness Ltd.

26 Feb 2025

2023.70

0.61%

Zydus Lifesciences to launch VaxiFlu-4 for new influenza strain

Business Line

The vaccine has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad and is being marketed by Zydus Vaxxicare

Zydus Wellness Ltd. has an average target of 2054.00 from 3 brokers.

Zydus launches vaccine for protection against new strain of influenza virus

Business Standard | 26 Feb 2025

Zydus Wellness Ltd.

13 Feb 2025

2023.70

0.61%

Mixed bag Q3

Buy: Zydus Wellness Ltd.

Target

Sharekhan

Zydus Wellness Limited’s (ZWL’s) Q3FY25 numbers were mixed with revenue beating estimates and growing by 14.6% y-o-y to Rs. 462 crore (versus expectation of Rs. 435 crore), while OPM stood flat y-o-y at 3.1% and missed expectations of 5.8%. Volume growth stood at 4.8%.

Zydus Wellness Ltd. is trading above all available SMAs

Zydus Wellness Ltd.

12 Feb 2025

2023.70

0.61%

Zydus Lifesciences Signs Exclusive Pact With Synthon BV For Novel Oncology Product

NDTV Profit

Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product. Zydus will be responsible for the NDA submission and commercialisation of the product in the US, it added.

Zydus Wellness Ltd. has an average target of 2054.00 from 3 brokers.

Zydus Wellness Ltd.

06 Feb 2025

2023.70

0.61%

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Business Standard

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said